These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 18448203)

  • 1. 'Sum of activities' as dependent parameter: a new CoMFA-based approach for the design of pan PPAR agonists.
    Sundriyal S; Bharatam PV
    Eur J Med Chem; 2009 Jan; 44(1):42-53. PubMed ID: 18448203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Important pharmacophoric features of pan PPAR agonists: common chemical feature analysis and virtual screening.
    Sundriyal S; Bharatam PV
    Eur J Med Chem; 2009 Sep; 44(9):3488-95. PubMed ID: 19268404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Receptor-based 3D-QSAR studies of checkpoint Wee1 kinase inhibitors.
    Wichapong K; Lindner M; Pianwanit S; Kokpol S; Sippl W
    Eur J Med Chem; 2009 Apr; 44(4):1383-95. PubMed ID: 18976834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel strategy for designing the selective PPAR agonist by the "sum of activity" model.
    Huang HJ; Lee KJ; Yu HW; Chen HY; Tsai FJ; Chen CY
    J Biomol Struct Dyn; 2010 Oct; 28(2):187-200. PubMed ID: 20645652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3D-QSAR and molecular docking studies of selective agonists for the thyroid hormone receptor beta.
    Du J; Qin J; Liu H; Yao X
    J Mol Graph Model; 2008 Sep; 27(2):95-104. PubMed ID: 18436460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CoMFA analysis of dual/multiple PPAR activators.
    Shah P; Mittal A; Bharatam PV
    Eur J Med Chem; 2008 Dec; 43(12):2784-91. PubMed ID: 18321611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2D QSAR of PPARgamma agonist binding and transactivation.
    Rücker C; Scarsi M; Meringer M
    Bioorg Med Chem; 2006 Aug; 14(15):5178-95. PubMed ID: 16650995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 3D-QSAR and molecular docking study on bisarylmaleimide series as glycogen synthase kinase 3, cyclin dependent kinase 2 and cyclin dependent kinase 4 inhibitors: an insight into the criteria for selectivity.
    Dessalew N; Bharatam PV
    Eur J Med Chem; 2007 Jul; 42(7):1014-27. PubMed ID: 17335939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Additivity of molecular fields: CoMFA study on dual activators of PPARalpha and PPARgamma.
    Khanna S; Sobhia ME; Bharatam PV
    J Med Chem; 2005 Apr; 48(8):3015-25. PubMed ID: 15828840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative structure-activity relationships for PPAR-gamma binding and gene transactivation of tyrosine-based agonists using multivariate statistics.
    Giaginis C; Theocharis S; Tsantili-Kakoulidou A
    Chem Biol Drug Des; 2008 Oct; 72(4):257-64. PubMed ID: 18793305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural and chemical basis for enhanced affinity and potency for a large series of estrogen receptor ligands: 2D and 3D QSAR studies.
    Salum Lde B; Polikarpov I; Andricopulo AD
    J Mol Graph Model; 2007 Sep; 26(2):434-42. PubMed ID: 17349808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement of the transactivation activity of phenylpropanoic acid-type peroxisome proliferator-activated receptor pan agonists: effect of introduction of fluorine at the linker part.
    Kasuga J; Oyama T; Hirakawa Y; Makishima M; Morikawa K; Hashimoto Y; Miyachi H
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4525-8. PubMed ID: 18662876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combinatorial QSAR modeling of specificity and subtype selectivity of ligands binding to serotonin receptors 5HT1E and 5HT1F.
    Wang XS; Tang H; Golbraikh A; Tropsha A
    J Chem Inf Model; 2008 May; 48(5):997-1013. PubMed ID: 18470978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-activity relationships of dimeric PPAR agonists.
    Sauerberg P; Mogensen JP; Jeppesen L; Svensson LA; Fleckner J; Nehlin J; Wulff EM; Pettersson I
    Bioorg Med Chem Lett; 2005 Mar; 15(5):1497-500. PubMed ID: 15713415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity landscape modeling of PPAR ligands with dual-activity difference maps.
    Méndez-Lucio O; Pérez-Villanueva J; Castillo R; Medina-Franco JL
    Bioorg Med Chem; 2012 Jun; 20(11):3523-32. PubMed ID: 22564380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3D-QSAR studies of boron-containing dipeptides as proteasome inhibitors with CoMFA and CoMSIA methods.
    Zhu YQ; Lei M; Lu AJ; Zhao X; Yin XJ; Gao QZ
    Eur J Med Chem; 2009 Apr; 44(4):1486-99. PubMed ID: 18771818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SAR-oriented discovery of peroxisome proliferator-activated receptor pan agonist with a 4-adamantylphenyl group as a hydrophobic tail.
    Kasuga J; Yamasaki D; Ogura K; Shimizu M; Sato M; Makishima M; Doi T; Hashimoto Y; Miyachi H
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1110-5. PubMed ID: 18162399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Modeling Study for the Design of Novel Peroxisome Proliferator-Activated Receptor Gamma Agonists using 3D-QSAR and Molecular Docking.
    Jian Y; He Y; Yang J; Han W; Zhai X; Zhao Y; Li Y
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29473866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three-dimensional QSAR analyses of 1,3,4-trisubstituted pyrrolidine-based CCR5 receptor inhibitors.
    Zhuo Y; Kong R; Cong XJ; Chen WZ; Wang CX
    Eur J Med Chem; 2008 Dec; 43(12):2724-34. PubMed ID: 18538451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CoMFA and HQSAR studies on 6,7-dimethoxy-4-pyrrolidylquinazoline derivatives as phosphodiesterase10A inhibitors.
    Kulkarni SS; Patel MR; Talele TT
    Bioorg Med Chem; 2008 Apr; 16(7):3675-86. PubMed ID: 18299198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.